All In Biotech

Drug Trial Radar · NCT06656702

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Apr 9, 2025

Primary completion

Jan 30, 2027

Study completion Jul 1, 2027

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Department of Defense; Congressionally Directed Medical Research Programs
First posted
Oct 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • PsilocybinDrug

    Psilocybin Trihydrate. Participants will complete an 8-week course of study treatment including two psilocybin sessions (15 mg in week 4 and 15 or 25 mg in week 6), with follow-up assessments 1, 3, and 6 months after the final psilocybin session.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility of psilocybin treatment as assessed by number of participants recruited, retained and adhere to treatmentTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins Center for Psychedelic and Consciousness Research

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.